Urinary protein biomarker panel for the detection of recurrent bladder cancer

Cancer Epidemiology Biomarkers and Prevention

Volumn 23, Issue 7, 2014, Pages 1340-1345

  Rosser, Charles J ^a,c,e   Chang, Myron ^b   Dai, Yunfeng ^b   Ross, Shanti ^a   Mengual, Lourdes ^f   Alcaraz, Antonio ^f   Goodison, Steve ^a,b,d  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c Nonagen Bioscience Corp   (United States)

^d MAYO CLINIC   (United States)

^e UNIVERSITY OF HAWAII CANCER CENTER   (United States)

^f UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIN; APOLIPOPROTEIN E; CARBONATE DEHYDRATASE IX; GELATINASE B; INTERLEUKIN 8; PLASMINOGEN ACTIVATOR INHIBITOR 1; STROMELYSIN 2; SYNDECAN 1; TUMOR MARKER; VASCULOTROPIN A;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER RECURRENCE; CREATININE URINE LEVEL; DIAGNOSTIC TEST ACCURACY STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN URINE LEVEL; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; URINE CYTOLOGY; AREA UNDER THE CURVE; BLADDER TUMOR; CLINICAL TRIAL; MIDDLE AGED; PATHOLOGY; TRANSITIONAL CELL CARCINOMA; TUMOR RECURRENCE; URINE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; AREA UNDER CURVE; BIOMARKERS, TUMOR; CARCINOMA, TRANSITIONAL CELL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RETROSPECTIVE STUDIES; ROC CURVE; URINARY BLADDER NEOPLASMS;

EID: 84904011624     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-14-0035     Document Type: Article

References (28)

1. Zaher A, Sheridan T. Tumor markers in the detection of recurrent transitional cell carcinoma of the bladder: a brief review. Acta Cytol 2001;45: 575-81.
2. Surveillance, Epidemiology, and End Results Program. [cited 2013 Dec 16] Available from: http://www.seer.cancer.gov/csr/1975-010/.
3. Yang N, Feng S, Shedden K, Xie X, Liu Y, Rosser CJ, et al. Urinary glycoprotein biomarker discovery for bladder cancer detection using LC/MS-MS and label-free quantification. Clin Cancer Res 2011;17: 3349-9.
4. Urquidi V, Goodison S, Cai Y, Sun Y, Rosser CJ. A candidate molecular biomarker panel for the detection of bladder cancer. Cancer Epidemiol Biomarkers Prev 2012;21: 2149-8
5. Rosser CJ, Liu L, Sun Y, Villicana P, McCullers M, Porvasnik S, et al. Bladder cancer-Associated gene expression signatures identified by profiling of exfoliated urothelia. Cancer Epidemiol Biomarkers Prev 2009;18: 444-3
6. Urquidi V, Kim J, Chang M, Dai Y, Rosser CJ, Goodison S. CCL18 in a multiplex urine-based assay for the detection of bladder cancer. PLoS One 2012;7: e37797.
7. Goodison S, Chang M, Dai Y, Urquidi V, Rosser CJ. A multi-Analyte assay for the non-invasive detection of bladder cancer. PLoS One 2012;7: e47469.
8. Rosser CJ, Ross S, Chang M, Dai Y, Mengual L, Zhang G, et al. Multiplex protein signature for the detection of bladder cancer in voided urine samples. J Urol 2013;190: 2257-62
9. Mengual L, Ribal MJ, Lozano JJ, Ingelmo-Torres M, Burset M, Fern-Andez PL, et al. Validation study of a noninvasive urine test for diagnosis and prognosis assessment of bladder cancer: evidence for improved models. J Urol 2014;191: 261-9.
10. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer 2005;93: 387-91.
11. Reid CN, Stevenson M, Abogunrin F, Ruddock MW, Emmert-Streib F, Lamont JV, et al. Standardization of diagnostic biomarker concentrations in urine: the hematuria caveat. PLoS One 2012;7: e53354.
12. McQuarrie ADR, Tsai CL. Regression and time series model selection. River Edge, NJ: World Scientific; 1998.
13. Edgar R, Domrachev M, Lash AE. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res 2002;30: 207-0.
14. Hall MC, Chang SS, Dalbagni G, Pruthi RS, Seigne JD, Skinner EC, et al. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol 2007;178: 2314-0.
15. Zuiverloon TC, van der Aa MN, van der Kwast TH, Steyerberg EW, Lingsma HF, Bangma CH, et al. Fibroblast growth factor receptor 3 mutation analysis on voided urine for surveillance of patients with lowgrade non-muscle-invasive bladder cancer. Clin Cancer Res 2010;16: 3011-8.
16. JochamD, Stepp H, Waidelich R. Photodynamic diagnosis in urology: state-of-The-Art. Eur Urol 2008;53: 1138-8.
17. Avritscher EB, Cooksley CD, Grossman HB, Sabichi AL, Hamblin L, Dinney CP, et al. Clinical model of lifetime cost of treating bladder cancer and associated complications. Urology 2006;68: 549-3.
18. Lotan Y, Svatek RS, Sagalowsky AI. Should we screen for bladder cancer in a high-risk population?: A cost per life-year saved analysis. Cancer 2006;107: 982-90.
19. Svatek RS, Sagalowsky AI, Lotan Y. Economic impact of screening for bladder cancer using bladder tumor markers: a decision analysis. Urol Oncol 2006;24: 338-3.
20. Stein M, Lubetkin D, Taub HC, Skinner WK, Haberman J, Kreutzer ER. The effects of intraurethrallidocaine anesthetic and patient anxiety on pain perception during cystoscopy. J Urol 1994;151: 1518-1.
21. Schrag D, Hsieh LJ, Rabbani F, Bach PB, Herr H, Begg CB. Adherence to surveillance among patients with superficial bladder cancer. J Natl Cancer Inst 2003;95: 588-97.
22. Nakamura K, Kasraeian A, Iczkowski KA, Chang M, Pendleton J, Anai S, et al. Utility of serial urinary cytology in the initial evaluation of the patient with microscopic hematuria. BMC Urol 2009;9: 12.
23. Kumar A, Kumar R, Gupta NP. Comparison of NMP22 BladderChek test and urine cytology for the detection of recurrent bladder cancer. Jpn J Clin Oncol 2006;36: 172-5.
24. Raitanen MP, Aine R, Rintala E, Kallio J, Rajala P, Juusela H, et al. Differences between local and review urinary cytology in diagnosis of bladder cancer. An interobserver multicenter analysis. Eur Urol 2002;41: 284-9.
25. Jones TD, Wang M, Eble JN, MacLennan GT, Lopez-Beltran A, Zhang S, et al. Molecular evidence supporting field effect in urothelial carcinogenesis. Clin Cancer Res 2005;11: 6512-9.
26. Cianciulli AM, Leonardo C, Guadagni F, Marzano R, Iori F, De Nunzio C, et al. Genetic instability in superficial bladder cancer and adjacent mucosa: an interphase cytogenetic study. Hum Pathol 2003;34: 214-1.
27. Todenhofer T, Hennenlotter J, Aufderklamm S, Kuhs U, Gakis G, Germann M, et al. Individual risk assessment in bladder cancer patients based on a multi-marker panel. J Cancer Res Clin Oncol 2013;139: 49-6.
28. Todenhofer T, Hennenlotter J, Kuhs U, Tews V, Gakis G, Aufderklamm S, et al. Influence of urinary tract instrumentation and inflammation on the performance of urine markers for the detection of bladder cancer. Urology 2012;79: 620-4.